Efficacy of allogeneic SCT in FLT3/ITD-positive AML. (A) Relapse risk (solid lines) and overall survival (shaded lines) in recipients of MFD SC transplant with and without FLT3/ITD. (B) Relapse risk (solid lines) and overall survival (shaded lines) in patients with FLT3/ITD treated with consolidation chemotherapy versus MFD SCT.